MFDS Approves Korean BMS Ulcerative Colitis Treatment New Drug 'Zeposia'

The Ministry of Food and Drug Safety announced on the 24th that it has approved the new drug for ulcerative colitis treatment, "Zeposia Capsules (Ozanimod Hydrochloride)," developed by Korea BMS Pharmaceuticals.

The approved items include two products: the "Starter Pack," which combines the initial dose (0.23 mg, days 1?4) and the intermediate dose (0.46 mg, days 5?7), and the maintenance dose (0.92 mg, from day 8 onward). The medication is taken once daily.

Zeposia Capsules act as modulators of the sphingosine 1-phosphate receptor, working by preventing autoreactive lymphocytes from migrating to the gastrointestinal tract in ulcerative colitis patients exhibiting immune regulation abnormalities, thereby suppressing inflammation.

It is expected to expand treatment options for patients with moderate to severe active ulcerative colitis who do not adequately respond to conventional therapies such as corticosteroids, immunosuppressants, or biologics, or who have lost response or have intolerance to these treatments.

The Ministry of Food and Drug Safety stated, "We will continue to do our best to ensure that treatments with confirmed safety and efficacy are supplied promptly based on regulatory science expertise, thereby expanding treatment opportunities for patients."

This content was produced with the assistance of AI translation services.